AstraZeneca announces that Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy, has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for approval in the EU for the first-line treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).

This recommendation is based on the results of a Phase III trial showing a 38% reduction in the risk of disease progression or death compared with Tagrisso monotherapy.

Median progression-free survival was 25.5 months with the chemotherapy combination, compared with 16.7 months with monotherapy.

"Today's news reinforces the importance of Tagrisso as a core therapy in EGFR-mutated lung cancer," commented Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca.

Copyright (c) 2024 CercleFinance.com. All rights reserved.